home
顺序
主题
题目
日子
106
HLB gets positive Phase 3 data with liver cancer treatment
admin
2022.05.16
105
Elevar Therapeutics to announce Phase 2 Results of Rivoceranib on ACC at ASCO
admin
2022.04.29
104
Immunomic Therapeutics approaches First-In-Human Trial for Merkel Cell Carcinoma
admin
2022.04.28
103
HLB posts earnings surprise in Q1
admin
2022.04.26
102
AACR reveals a 'Real-World Data' of Rivoceranib's Efficacy and safety in HCC
admin
2022.04.11
101
HLB leads social responsibility management by joining UNGC
admin
2022.03.16
100
Elevar Therapeutics Announces Key Management changes
admin
2022.03.15
99
HLB receives first Rivoceranib royalty from Chinese Hengrui Pharmaceutical
admin
2022.03.08
98
HLB U.S. subsidiary Immunomic gets FDA approval for IND application for Merkel cell cancer treatment
admin
2022.02.04
97
HLB completed the acquisition of FA, highly expected to turn into a surplus this year
admin
2022.01.04